Agilus Diagnostics to withdraw DRHP filed with market regulator Sebi

Agilus Diagnostics to withdraw DRHP filed with market regulator Sebi
Business Standard
Published onBusiness Standard
Publish Date14 February 2024
Reading time1 Min

Share on Social Links

Category

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Diagnostic services provider Agilus Diagnostics announced on Tuesday that it will withdraw its draft red herring prospectus (DRHP) filed with the Securities and Exchange Board of India (Sebi). After the decision was announced late Tuesday night, Fortis Healthcare stock fell 3.23 percent in morning trade around 11 am. The company said in its regulatory filing that the decision to withdraw the DRHP has been taken due to commercial considerations and in consultation and mutual agreement with the private equity investors of Agilus and its board of directors, the company said in a regulatory filing on the Bombay Stock Exchange (BSE).

Tags

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Stay Connected, Stay Informed –

Join Our

WhatsApp

Channel!

Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.

Pre Ipo

Pre Ipo

Upcoming IPO

Upcoming IPO

Unicorn

Unicorn